RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. [electronic resource]
Producer: 20080908Description: 2160-9 p. digitalISSN:- 1535-7163
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Bone Neoplasms -- complications
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Docetaxel
- Humans
- Male
- Mice
- Mice, Nude
- Osteolysis -- complications
- Osteoprotegerin -- pharmacology
- Prostatic Neoplasms -- pathology
- RANK Ligand -- antagonists & inhibitors
- Receptors, Fc
- Survival Analysis
- Taxoids -- pharmacology
- Tumor Burden -- drug effects
- Whole Body Imaging
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.